Publication

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Publications associées (29)

Virtual reality intervention alleviates dyspnoea in patients recovering from COVID-19 pneumonia

Bruno Herbelin, Olaf Blanke, Sylvain Cardin, Oliver Alan Kannape, Jemina Fasola, Aline Schmit, Florian Lance, Sophie Jacqueline Andrée Betka

Background Immersive virtual reality (iVR)-based digital therapeutics are gaining clinical attention in the field of pain management. Based on known analogies between pain and dyspnoea, we investigated the effects of visual respiratory feedback on persiste ...

European Respiratory Soc Journals Ltd2023

Unlocking Hidden Potential: Exploring the Complexities of Signaling in Immune Cell Activation to Optimize CAR Therapy

Mathieu Girardin

Chimeric antigen receptors (CARs) are synthetic, transmembrane proteins that trigger immune cell signaling following their engagement. They have been first utilized in T cells and later in natural killer (NK) cells to redirect their cytotoxicity toward a s ...

EPFL2023

Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes

Julien Racle, David Gfeller, Philippe Guillaume Coune, Florence Pojer, Marta Andreia Da Silva Perez, George Coukos, Kelvin Ka Ching Lau, Amédé Noredine Larabi, Alexandre Harari

CD4+T cells orchestrate the adaptive immune response against pathogens and cancer by recognizing epitopes presented on class II major histocompatibility complex (MHC-II) molecules. The high polymorphism of MHC-II genes represents an important hurdle toward ...

CELL PRESS2023

Preliminary evidence that daily light exposure enhances the antibody response to influenza vaccination in patients with dementia

Jean-Louis Scartezzini

Enhancing lighting conditions in institutions for individuals with dementia improves their sleep, circadian rhythms and well-being. Here, we report first findings that exposure to brighter light during daytime may support the immune response to the annual ...

ELSEVIER2022

A Baseline Cellular Antiviral State Is Maintained by cGAS and Its Most Frequent Naturally Occurring Variant rs610913

Shuting Xu, Jacques Fellay, Christian Axel Wandall Thorball

Upon recognition of aberrantly located DNA, the innate immune sensor cyclic GMP-AMP synthase (cGAS) activates stimulator of IFN genes (STING)/IFN regulatory factor (IRF)3-driven antiviral responses. In this study, we characterized the ability of a specific ...

American Association of Immunologists ; Oxford University Press2022

The cGAS–STING pathway drives type I IFN immunopathology in COVID-19

Kunal Sharma, Andrea Ablasser, Muhammet Fatih Gülen, Vivek Vijay Thacker, Théo Nass, Martin Schaller

COVID-19, which is caused by infection with SARS-CoV-2, is characterized by lung pathology and extrapulmonary complications1,2. Type I interferons (IFNs) have an essential role in the pathogenesis of COVID-19 (refs 3–5). Although rapid induction of type I ...

2022

Expiratory Aerosol pH: The Overlooked Driver of Airborne Virus Inactivation

Tamar Kohn, Aline Laetitia Schaub, Athanasios Nenes, Kalliopi Violaki, Shannon Christa David, Ghislain Gilles Jean-Michel Motos, Walter Hugentobler

Respiratory viruses, including influenza virus and SARS-CoV-2, are transmitted by the airborne route. Air filtration and ventilation mechanically reduce the concentration of airborne viruses and are necessary tools for disease mitigation. However, they ign ...

2023

Protein Engineering for Personalized therapy and diagnosis

Lixia Wei

Protein Engineering, especially protein post-translational modification (PTM), ex-tends proteomes in a more complex way than one can expect from analysis of their encod-ing genomes. It can activate or deactivate certain catalytic functions, add new desired ...

EPFL2022

Variability of Primary Sjogren's Syndrome Is Driven by Interferon alpha and Interferon alpha Blood Levels Are Associated With the Class II HLA-DQ Locus

Nicolas Meyer, Jacques Fellay, Christian Axel Wandall Thorball

Objective Primary Sjogren's syndrome (SS) is the second most frequent systemic autoimmune disease, affecting 0.1% of the general population. To characterize the molecular and clinical variabilities among patients with primary SS, we integrated transcriptom ...

WILEY2022